GHIT Fund Global Health Innovative Technology Fund

Investments

Clinical Candidates

Eight GHIT development partnerships have conducted successful late-stage projects in Africa and South America. As a result, and numerous promising global health innovations are now firmly within reach.

DSM265
Malaria / Drug
Development Stage: Phase IIb
Country: To be determined
https://www.ghitfund.org/investment/portfoliodetail/detail/112/en
E1224
Chagas disease / Drug
Development Stage: Phase IIb
Country: Bolivia
https://www.ghitfund.org/investment/portfoliodetail/detail/26/en
PZQ
Schistosomiasis / Pediatric Drug
Development Stage: Phase Ⅲ
Country: Ivory Coast, Kenya, Zimbabwe
https://www.ghitfund.org/investment/portfoliodetail/detail/103/en
DAR-901
Tuberculosis / Vaccine
Development Stage: Phase IIb
Country: Tanzania
https://www.ghitfund.org/investment/portfoliodetail/detail/70/en
BK-SE36/CpG
Malaria / Vaccine
Development Stage: Phase Ib
Country: Burkina Faso
https://www.ghitfund.org/investment/portfoliodetail/detail/99/en
SJ733
Malaria / Drug
Development Stage: Phase IIa
Country: To be determined
https://www.ghitfund.org/investment/portfoliodetail/detail/106/en
TB-LAM
Tuberculosis / Diagnostic
Development Stage: Product validation
Country: South Africa
https://www.ghitfund.org/investment/portfoliodetail/detail/126/en
E1224
Mycetoma / Drug
Development Stage: Phase IIb
Country: Sudan
https://www.ghitfund.org/investment/portfoliodetail/detail/114/en